Prognostic and predictive value of Phospho-p44/42 and pAKT in HER2-positive locally advanced breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy

Huang, Liang; Chen, Tianwen; Chen, Canming; Chen, Sheng; Liu, Yin; Wu, Jiong; Shao, Zhiming

doi:10.1186/1477-7819-11-307

Table 2 Univariate analysis of relapse-free survival and overall survival

From: Prognostic and predictive value of Phospho-p44/42 and pAKT in HER2-positive locally advanced breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy

Factor	Relapse-free survival		Overall survival		Factor	Relapse-free survival		Overall survival
	P	Hazard ratio (95% confidence interval)	P	Hazard ratio (95% confidence interval)		P	Hazard ratio (95% confidence interval)	P	Hazard ratio (95% confidence interval)
Age
<45y vs. ≥45y	0.724	1.2 (0.5 to 2.7)	0.256	1.0 (0.9 to 1.0)
Menopausal status
Premenopausal vs. Postmenopausal	0.663	0.9 (0.5 to 1.5)	0.822	1.0 (0.6 to 2.0)
Regimen
CEF vs. NE	0.479	1.2 (0.7 to 2.0)	0.568	1.2 (0.6 to 2.2)
Tumor size
≤5 cm vs. >5 cm	0.784	1.1 (0.6 to 2.0)	0.456	1.3 (0.6 to 2.8)
Lymph node status
Negative
1 to 3 nodes +	0.007	2.7 (1.3 to 5.6)	0.012	4.3 (1.4 to 13.3)
4 to 9 nodes +	<0.001	4.6 (2.2 to 9.5)	0.001	7.2 (2.4 to 21.9)
≥10 nodes +	<0.001	6.8 (3.0 to 15.9)	<0.001	13.7 (4.3 to 44.4)
Pre-estrogen receptor					Post-estrogen receptor
Negative vs. positive	0.252	1.4 (0.8 to 2.3)	0.620	1.2 (0.6 to 2.2)	Negative vs. positive	1.000	1.0 (0.5 to 1.8)	0.540	0.8 (0.4 to 1.7)
Pre-progesterone receptor					Post-progesterone receptor
Negative vs. positive	0.724	0.9 (0.5 to 1.6)	0.334	0.7 (0.3 to 1.5)	Negative vs. positive	0.841	1.0 (0.6 to 2.0)	0.754	0.9 (0.4 to 2.0)
Pre-Ki67					Post-Ki67
Negative vs. positive	0.840	1.1 (0.6 to 1.8)	0.647	0.9 (0.5 to 1.6)	Negative vs. positive	0.260	1.4 (0.8 to 2.3)	0.434	1.3 (0.7 to 2.4)
Pre-pMAPK					Post-pMAPK
Negative vs. positive	0.174	0.7 (0.4 to 1.2)	0.788	1.1 (0.6 to 2.2)	Negative vs. positive	0.019	2.0 (1.1 to 3.5)	<0.001	3.7 (1.9 to 7.0)
Pre-pAKT					Post-pAKT
Negative vs. positive	0.224	0.7 (0.4 to 1.2)	0.104	0.6 (0.3 to 1.1)	Negative vs. positive	0.551	0.8 (0.5 to 1.5)	0.548	0.8 (0.4 to 1.7)
Pre-PTEN					Post-PTEN
Negative vs. positive	0.450	0.8 (0.5 to 1.4)	0.538	0.8 (0.4 to 1.5)	Negative vs. positive	0.622	0.9 (0.5 to 1.6)	0.571	1.3 (0.6 to 2.7)
Pre-P27					Post-P27
Negative vs. positive	0.929	1.0 (0.6 to 1.6)	0.439	0.8 (0.4 to 1.5)	Negative vs. positive	0.220	1.4 (0.8 to 2.5)	0.317	1.4 (0.7 to 2.9)
Pre-IGF-1R					Post-IGF-1R
Negative vs. positive	0.728	1.1 (0.7 to 1.8)	0.874	1.1 (0.6 to 2.0)	Negative vs. positive	0.388	0.8 (0.5 to 1.3)	0.760	1.1 (0.6 to 2.2)
Pre-cyclinD1					Post-cyclinD1
Negative vs. positive	0.606	1.2 (0.7 to 2.0)	0.814	1.1 (0.6 to 2.1)	Negative vs. positive	0.602	1.2 (0.7 to 2.1)	0.912	1.0 (0.5 to 2.1)

IGF-1R, insulin-like growth factor 1 receptor; pAKT, phosphorylated AKT; pMAPK, phosphorylated mitogen-activated protein kinase.

Back to article page

ISSN: 1477-7819

Contact us

General enquiries: journalsubmissions@springernature.com

World Journal of Surgical Oncology

Contact us